EryDel announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study
EryDel Appoints Antonio Ferrari, MD, as Global Medical Director
EryDel Consortium gains Euro 6 million Funding for development of EDS for the treatment of Ataxia Telangiectasia
Long term benefit of erytrocyte-delivered dexamathasone in Ataxia Telangiectasia
EryDel expands Series B financing to 29.5M
EryDel appoints René Goedkoop, MD, as Chief Medical Officer
Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases
EryDel selected as one of the top five candidates in 2013 EuropaBio Most Innovative EU Biotech SME Award
Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)
EryDel SpA Completes €15 Million Series B financing
EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia
The Stainig procedures brochure, is now availables for downloading in the Documents section.
The Injectable Saline Adaptor for EryKit_01 Instruction For Use - all languages - is now available for downloading in the Documents section.